Nycomed is a privately owned, global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.

Its R&D is built to be open for partnerships beyond its core areas in inflammatory, respiratory diseases and pain as in-licensing is a cornerstone of the company’s growth strategy.
Nycomed is present in over 50 countries worldwide, and its products are available in more than 100 countries.

The company employs 12,000 associates. In 2008, it had annual sales of € 3.4 billion and an adjusted EBITDA of € 1.2 billion.